leisure time -WSS

leisure time

author：hotspot 2025-09-06 04:37:48 - browse：85

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a week, indefinitely. But what if they could be taken once a year instead, like a vaccine?

That’s a question that Novo Nordisk, the pharma company behind Wegovy, is exploring as it faces increased competition from other drugmakers aiming to develop similar GLP-1-based treatments for obesity.

“We have a very early think tank on: what would it take us, from a technology point of view and from an ecosystem point of view, to make long-lasting GLP-1 molecules?” Marcus Schindler, Novo’s chief scientific officer, said in an interview with STAT Wednesday. “Could we think about vaccine-like properties, where imagine you had, once a year, an injection with an equivalent of a GLP-1 that really helps you to maintain weight loss and have cardiovascular benefits?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Stopping antidepressants leads to symptoms for 1 in 6 patients

leisure time

WSS

Senators tussle over abortion against the backdrop of a presidential campaign

The most pressing bird flu mysteries scientists want answered

Senators tussle over abortion against the backdrop of a presidential campaign

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

Structure Therapeutics oral GLP

Medicare slashes safety net hospital payments by nearly $1 billion

knowledge

leisure time

hotspot

Psychedelics group wrestles with new pharma identity

CMS got Medicare Advantage quality rating wrong, judge rules

How one medical school became remarkably diverse

Pharma showers House GOP doctor with campaign cash

Medical leaders decry Supreme Court decision on affirmative action

The cancer stories no one wants to hear

Medical leaders decry Supreme Court decision on affirmative action

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

At least 13 dead in Texas as scorching temps continue

Late stage cancers on the rise after pandemic delayed screenings

hotspot

Biotech startup Celsius cuts 75% of staff ahead of first trial start

2 officers injured in shooting in Orlando, police say

Anthony Fauci pushes back on GOP claims during Covid hearing

Illumina board agrees to spin off Grail, as divestment plans proceed

The cancer stories no one wants to hear

FDA approves Sage Therapeutics’ rapid

explore

leisure time

leisure time

entertainment